One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Jasper Therapeutics, Inc.
JSPR · NCM · Healthcare · Biotechnology
Current price
$0.56
52-week range
$0.32 - $2.69
Market cap
$18.47M
Balance sheet
Distressed
-48.18x Concerning
Net cash $0.00. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
0 Risks
0 rewards · 0 risks
Highlights are unavailable right now.
What this company does
Jasper Therapeutics, Inc.
Jasper Therapeutics is a company working on new medicines to help people with immune system problems, like those who have trouble making new blood cells or suffer from severe allergies. Their main money comes from research and development funding, meaning they get money to discover and test these new drugs, which is important because it allows them to continue their work on potentially life-changing treatments.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
Revenue
—
Net income
$-2.76M
Diluted EPS
-0.10
Operating cash flow
$-6.92M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-1.17M
Diluted EPS
-0.04
Operating cash flow
$-14.55M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-9.10M
Diluted EPS
0.33
Operating cash flow
$-21.87M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-18.74M
Diluted EPS
-1.13
Operating cash flow
$-17.00M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-26.72M
Diluted EPS
-1.74
Operating cash flow
$-15.45M
Free cash flow
$-15.46M
Fetching…
Sources
Revenue
—
Net income
$-21.24M
Diluted EPS
-1.41
Operating cash flow
$-22.84M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-24.32M
Diluted EPS
-1.65
Operating cash flow
$-21.13M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-18.64M
Diluted EPS
-1.24
Operating cash flow
$-14.05M
Free cash flow
—
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.56
We couldn't calculate a fair value right now.
Is it drowning in debt?
Distressed
Net cash $0 - more cash than debt. Interest coverage -48.2x.
Net debt
$0.00
Interest coverage
-48.18x
Jasper Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 3 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Distressed
Worse cushion
Baseline
Better cushion
JSPR
BASELINE
Jasper Therapeutics, Inc.
Total debt — Interest coverage -48.18x This is the baseline the peer rows are being compared against.
Total debt $1.04M Interest coverage -15.06x Neither company has much profit cushion over interest right now.
Total debt $15.51M Interest coverage -16.10x Neither company has much profit cushion over interest right now.
Total debt $247.36M Interest coverage -8.77x Neither company has much profit cushion over interest right now.
Total debt $2.71B Interest coverage 84.52x This peer still has a real interest-payment cushion, while JSPR does not.
Total debt $1.98B Interest coverage 342.44x This peer still has a real interest-payment cushion, while JSPR does not.
What you should know
The case for and against JSPR
0 Rewards
0 Risks
Rewards
Risks
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.22x
P/B
11.10x
P/S
—
EV/EBITDA
—
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
—
ROA
—
Health
Liquidity and balance-sheet strength
Debt / equity
—
Current ratio
—
Quick ratio
—
Total debt
—
Total cash
—
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.04
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-60.33M
Free CF TTM
$-77.17M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
0.0%
Last ex-div date
—